Platinum-based chemotherapy was previously the first-choice treatment for lung cancer. The
discovery of epidermal growth factor receptor (EGFR) gene mutations and the development …

The advent of targeted therapies for oncogenic mutations has led to a major paradigm shift
in the management of non–small cell lung cancer (NSCLC). Molecular targets, such as …

Although targeted therapy is standard of care in a large subset of oncogenic addicted non-
small cell lung cancers (NSCLC), until recently, this therapeutic approach has not been …

Approximately 10% of EGFR-activating mutations occur as in-frame insertion mutations in
exon 20 of the EGFR kinase domain (EGFR ins20). EGFR ins20 mutations have not …

Epidermal growth factor receptor (EGFR) mutation is one of the key oncogenic mutations in
non-small-cell lung cancer with adenocarcinoma histology. Exon 19 deletions and exon 21 …

Background Epidermal growth factor receptor gene (EGFR) exon 20 insertion (ex20-ins)
mutations are an uncommon and heterogeneous group of non–small cell lung cancers …

Introduction EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC)
is rare, has a poor prognosis, and outcomes are not fully established. We describe and …

Background Two main categories of epidermal growth factor receptor (EGFR) mutations in
non–small-cell lung cancer (NSCLC) patients are deletions in exon 19 and L858R in exon …

Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (Exon20ins) account
for 4–12% of all EGFR mutations in non-small cell lung cancer (NSCLC) patients. Data on …

Objectives The burden of epidermal growth factor receptor (EGFR) exon 20 insertion
mutation (Exon 20ins) in non-small cell lung cancer is not well understood. A systematic …